Are you Dr. Honarpour?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
Ucla Med Cardio
Box 951679, Bh-307 Chs
Los Angeles, CA 90095Phone+1 310-825-5280
Summary
- Dr. Narimon Honarpour, MD is a cardiologist in Los Angeles, California. He is currently licensed to practice medicine in California.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Cardiovascular Disease, 2005 - 2010
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2003 - 2006
- University of Texas Southwestern Medical SchoolClass of 2003
Certifications & Licensure
- CA State Medical License 2005 - 2024
Publications & Presentations
PubMed
- 3384 citationsEvolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S. Sabatine, Robert P. Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D. Wiviott
The New England Journal of Medicine. 2017-03-17 - 194 citationsChronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trialJohn R. Teerlink, G. Michael Felker, John J.V. McMurray, Scott D. Solomon, Kirkwood F. Adams
Lancet. 2016-12-10 - 316 citationsCardiac myosin activation with omecamtiv mecarbil in systolic heart failureJohn R. Teerlink, Rafael Diaz, G. Michael Felker, John J.V. McMurray, Marco Metra
The New England Journal of Medicine. 2021-01-14
Authored Content
- Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
- Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
- Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
- Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
- Join now to see all
Press Mentions
- GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual DiseaseJanuary 11th, 2021
Professional Memberships
- Member